One of Indonesia's largest pharmaceutical company PT Kalbe Farma Tbk (KLBF) keeps maintaining its performance growth. In the first 9 months of 2010, Kalbe Farma posted a 46.5% jump in net profit to Rp902 billion from Rp616 billion in 9M 2009. Thanks to robust collaboration between higher revenue and controllable production cost.
Kalbe Farma Corporate Secretary Vidjongtius said earning per share remains positive with a 50% growth from Rp64 to Rp96. EBITDA keeps climbing 20.6% from Rp1.18 trillion in 9M 2009 to Rp1.43 trillion in 9M 2010.
Operating profit rose 22.3% from Rp1.05 trillion in 9M 2009 to Rp1.29 trillion, reflecting a growth margin from 16.2% to 17.7% as a result of controllable production cost as well as productivity advanced.
Gross profit also increased 16.7% from Rp3.19 trillion at the end of September 2009 to Rp3.73 trillion in 9M 2010, lifting gross margin from 49.2% to 51.2% in 9M 2010.
Kalbe Farma booked a 12% growth in revenue from Rp6.49 trillion in 9M 2009 to Rp7.27 trillion in 9M 2010
In term of nominal contribution, revenue coming from distribution and logistic division remained the largest. Still, nutrition business showed the highest growth of 22.6% and ethical division posted a 16.4% increase.
Disclosure: No position at the stock mentioned above.
Print This Article